infectious disease physician | epidemiologist | HIV prevention | Bay Area Sports fan | Mom | Views my own.
San Francisco, CA
Joined June 2016
- Tweets986
- Following629
- Followers1.2K
- Likes5.9K
Lillian Brown retweeted
Yesterday, at the International AIDS Conference (#AIDS2024) in Munich, we got one of those thrilling moments you hope for when attending a scientific conference -- but don't usually get!
Here's what happened. @LindaGailBekker @drmoupali
blogs.jwatch.org/hiv-id-obse…
Great write up of the PURPOSE-1 results by @PaulSaxMD highlighting the incredible results and the many innovative aspects of the trial design blogs.jwatch.org/hiv-id-obse…
2
1
134
Looking forward to PURPOSE-2 results in gender-diverse individuals! #preventionwithpurpose
1
1
65
Lillian Brown retweeted
👏 @DTHF_SA’s @LindaGailBekker 🇿🇦 receives a standing ovation after presenting full results from the PURPOSE 1 study. The results confirm #lenacapavir demonstrated 100% efficacy for #HIV prevention in cisgender women.
Lillian Brown retweeted
In the PURPOSE 1 randomized, controlled trial involving women in South Africa & Uganda, twice-yearly subcutaneous lenacapavir was superior to daily oral emtricitabine–tenofovir disoproxil fumarate in preventing HIV infection. Full trial results: nej.md/3zRElVj
#AIDS2024
ALT Bar chart of background HIV incidence and HIV incidence in lenacapavir, F/TAF, and F/TDF groups.
Lillian Brown retweeted
Zero is zero!!! Remarkable results of injectable lenacapavir for PrEP.
Now we must translate trial results into public health impact.
#AIDS2024 @LindaGailBekker @apha_sa @ICWEastAfrica
Lillian Brown retweeted
“The introduction of oral #PrEP has changed the lives of more than 6 million people globally who have accessed it.” - @iasociety Past President @LindaGailBekker 🇿🇦 #AIDS2024
Lillian Brown retweeted
📊 Today at #AIDS2024, Past IAS President @LindaGailBekker presents full results from PURPOSE 1 trial. The results confirm #lenacapavir demonstrated 100% efficacy for #HIV prevention in cisgender women.
Read IAS President & AIDS 2024 Int'l Co-Chair @ProfSharonLewin's statement.
Lillian Brown retweeted
Gilead's twice-yearly antiviral protected women from HIV infection. PURPOSE 1 study results seem to be fantastic. @statnews statnews.com/2024/06/20/hiv-…
Lillian Brown retweeted
We are deeply saddened by the passing of Adaora Adimora, MD, MPH, FIDSA. We were incredibly fortunate for her dedication to @IDSAinfo & HIVMA.
Lillian Brown retweeted
Today is World AIDS Day and after 32 years of living with HIV, I’m blessed to still be here! I’m proud of the progress made in HIV/AIDS research, medication, and funding. We still have a long way to go for a cure and in the fight against stigma in all communities, especially in Black and brown. There is no place in this world for discrimination against those living with HIV/AIDS. #WorldAIDSDay
Lillian Brown retweeted
#PrEP uptake is suboptimal. One problem is the difficulty providers have in supporting their patients' #sexual well-being. @michael_traeger @JuliaLMarcus @douglaskrakower and I discuss how to prioritize patients' experiences in this week's @LancetHIV
sciencedirect.com/science/ar…
Lillian Brown retweeted
At #IAS2023 symposium on next-generation trial design @drmoupali describes PURPOSE program to study lenacapavir for PrEP — and emphasizes early, committed and consistent community engagement — as per the Good Participatory Practice Guidelines #GPP avac.org/project/good-partic…
Lillian Brown retweeted
Research gets it Right when the community is engaged early. When the community is engaged throughout the process. When the community is trusted to deal with complicated challenges faced during trials.
Lillian Brown retweeted
.@GileadSciences' Kathryn Kersey 🇺🇸 outlines the two current trials on lenacapavir (LEN). It is a subcutaneous injection meaning that it could be a self-injection. The trials are looking at the efficacy of LEN as an injectable every 6-months. #IAS2023
